Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 11/20 | 0.52 |
| ▸ | F10 | P00742 | 8/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7114123 | 0.99 | NPY2R (0.52) | NPY2RF10PRSS1ALDH1A1TP53 | |
| SCHEMBL7526703 | 0.85 | F10 (0.53) | NPY2RF10PRSS1ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL7123462 | 0.84 | F10 (0.52) | NPY2RF10PRSS1ALDH1A1TP53 | |
| SCHEMBL7114110 | 0.82 | F10 (0.49) | NPY2RF10ALDH1A1 | |
| SCHEMBL6343546 | 0.80 | F10 (0.55) | NPY2RF10PRSS1ALDH1A1TP53 | |
| SCHEMBL7116677 | 0.79 | F10 (0.56) | F10PRSS1ALDH1A1TP53HPGD | |
| Hydrochloric Acid SCHEMBL5091270 | 0.79 | F10 (0.54) | NPY2RF10PRSS1ALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL7115571 | 0.78 | F10 (0.55) | F10PRSS1ALDH1A1TP53HPGD | |
| SCHEMBL3426678 | 0.78 | F10 (0.62) | NPY2RF10ALDH1A1TP53HPGD | |
| SCHEMBL7123484 | 0.76 | F10 (0.53) | F10PRSS1ALDH1A1TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | claimed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | claimed |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | disclosed |
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | EISERT WOLFGANG | 2009-02-19 | — | — | US | disclosed |
| EP-1885354-A2 | COMBINATIONS COMPRISING AT LEAST ONE DIRECT THROMBIN INHIBITOR FOR THE TREATMENT OF THROMBOSIS | Boehringer Ingelheim International GmbH (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1747016-A2 | USE OF DIPYRIDAMOLE FOR TREATMENT OF RESISTANCE TO PLATELET INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103206-A2 | COMBINATIONS COMPRISING AT LEAST ONE DIRECT THROMBIN INHIBITOR FOR THE TREATMENT OF THROMBOSIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005113006-A2 | USE OF DIPYRIDAMOLE FOR TREATMENT OF RESISTANCE TO PLATELET INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
| EP-1360170-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062748-A1 | CARBOXYLIC AMIDES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | ANXA5, F5, ANXA3 | NPY2R 2263/4885F10 112/4885PRSS1 333/4885 |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | PEPD, PLAT, TFPI | NPY2R 1658/4885F10 51/4885PRSS1 109/4885 |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | PROC, F12, SERPINC1 | NPY2R 917/4885F10 6/4885PRSS1 158/4885 |
| US-20060222640-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF THROMBOSIS | PROC, F12, SERPINC1 | NPY2R 917/4885F10 6/4885PRSS1 158/4885 |
| US-20020151595-A1 | Carboxylic acid amides having antithrombotic activity | SERPINC1, TFPI, F2 | NPY2R 651/4885F10 30/4885PRSS1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.